tiprankstipranks
Advertisement
Advertisement

GMAB Stock Latest News

Genmab (OTC) Maps Catalyst-Rich Path After Strong Q1
Company AnnouncementsGenmab (OTC) Maps Catalyst-Rich Path After Strong Q1
1d ago
GMAB
Analyst Maintains Buy on Genmab as Expanded Petosemtamab Phase III Program Strengthens Late-Stage HNSCC Outlook
PremiumRatings
Analyst Maintains Buy on Genmab as Expanded Petosemtamab Phase III Program Strengthens Late-Stage HNSCC Outlook
2d ago
GMAB
PremiumRatings
Genmab: Buy Rating Reiterated on Strong Clinical Catalysts, Unchanged DKK 2,500 Price Target
6d ago
GMAB
Genmab Earnings Call: Strong Growth, Big Pipeline Bets
PremiumCompany Announcements
Genmab Earnings Call: Strong Growth, Big Pipeline Bets
6d ago
GMAB
Genmab Updates Articles of Association, Expands Capital and Incentive Authorizations
PremiumCompany Announcements
Genmab Updates Articles of Association, Expands Capital and Incentive Authorizations
8d ago
6K
GMAB
Genmab Announces Minor Capital Increase Following Employee Warrant Exercise
PremiumCompany AnnouncementsGenmab Announces Minor Capital Increase Following Employee Warrant Exercise
9d ago
6K
GMAB
Genmab price target lowered to DKK 2,250 from DKK 2,400 at Deutsche Bank
Premium
The Fly
Genmab price target lowered to DKK 2,250 from DKK 2,400 at Deutsche Bank
10d ago
GMAB
Genmab announces 5.08% stake by Orbis Investment
Premium
The Fly
Genmab announces 5.08% stake by Orbis Investment
13d ago
GMAB
Genmab Discloses Orbis as 5.08% Major Shareholder
PremiumCompany Announcements
Genmab Discloses Orbis as 5.08% Major Shareholder
13d ago
6K
GMAB
Yaron Werber Reiterates Hold on Genmab, Citing Strong Execution but 2026‑Weighted Catalyst Risk Profile
PremiumRatings
Yaron Werber Reiterates Hold on Genmab, Citing Strong Execution but 2026‑Weighted Catalyst Risk Profile
13d ago
GMAB
Genmab Terminates Early-Stage GEN1057 Cancer Trial: What Investors Should Watch Next
PremiumCompany Announcements
Genmab Terminates Early-Stage GEN1057 Cancer Trial: What Investors Should Watch Next
13d ago
GMAB
Genmab Halts Early-Stage GEN1286 Cancer Trial: What Investors Should Know
PremiumCompany Announcements
Genmab Halts Early-Stage GEN1286 Cancer Trial: What Investors Should Know
13d ago
GMAB
Genmab price target lowered to $33 from $34 at Morgan Stanley
PremiumThe FlyGenmab price target lowered to $33 from $34 at Morgan Stanley
13d ago
GMAB
Genmab: Buy Rating Reiterated as 2026 Pivotal Data Catalysts and Strong Epkinly Momentum Make 15% Share Pullback an Attractive Entry Point
Premium
Ratings
Genmab: Buy Rating Reiterated as 2026 Pivotal Data Catalysts and Strong Epkinly Momentum Make 15% Share Pullback an Attractive Entry Point
13d ago
GMAB
Genmab reports Q1 operating profit $180M, consensus $172.7M
Premium
The Fly
Genmab reports Q1 operating profit $180M, consensus $172.7M
14d ago
GMAB
Genmab maintains FY26 guidance
PremiumThe Fly
Genmab maintains FY26 guidance
14d ago
GMAB
Genmab Advances Rina S Into Phase 2 GI Cancer Trial, Raising Long Term Pipeline Hopes
PremiumCompany Announcements
Genmab Advances Rina S Into Phase 2 GI Cancer Trial, Raising Long Term Pipeline Hopes
14d ago
GMAB
Genmab Posts Strong Q1 2026 Revenue Growth and Highlights FDA Label Change for EPKINLY
PremiumCompany Announcements
Genmab Posts Strong Q1 2026 Revenue Growth and Highlights FDA Label Change for EPKINLY
14d ago
6K
GMAB
Genmab price target lowered to $38 from $40 at H.C. Wainwright
PremiumThe Fly
Genmab price target lowered to $38 from $40 at H.C. Wainwright
21d ago
GMAB
Genmab: Buy Rating Backed by Expanded Petosemtamab-Keytruda Phase III Trial and Blockbuster Late-Stage Pipeline
PremiumRatingsGenmab: Buy Rating Backed by Expanded Petosemtamab-Keytruda Phase III Trial and Blockbuster Late-Stage Pipeline
24d ago
GMAB
Genmab upgraded to Outperform from Neutral at BNP Paribas
Premium
The Fly
Genmab upgraded to Outperform from Neutral at BNP Paribas
29d ago
GMAB
Genmab upgraded to Buy from Neutral at Goldman Sachs
Premium
The Fly
Genmab upgraded to Buy from Neutral at Goldman Sachs
29d ago
GMAB

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >